UC San Diego researchers have developed a device that predicts breast cancer aggressiveness by measuring tumor cell adhesion. Weakly adherent cells indicate a higher risk of metastasis, especially in early-stage DCIS. This innovation could help personalize treatments and improve cancer prognosis.
By evaluating the “stickiness” of tumor cells, researchers at the University of California, San Diego, have identified a potential method for predicting whether a patient’s early-stage breast cancer is likely to spread. This discovery, enabled by a specially designed microfluidic device, could help doctors identify high-risk patients and tailor their treatments accordingly.
The device, tested in an investigator-initiated trial, operates by pushing tumor cells through fluid-filled chambers and sorting them based on their ability to adhere to the chamber walls. When tested on tumor cells from patients at different stages of breast cancer, researchers observed a striking pattern: cells from patients with aggressive cancers were weakly adherent (less sticky), whereas cells from patients with less aggressive cancers were strongly adherent (more sticky).
The findings were published on March 5 in Cell Reports.
Potential for Improved Cancer Diagnosis
“What we were able to show in this trial is that the physical property of how adhesive tumor cells are could be a key metric to sort patients into more or less aggressive cancers,” said study senior author Adam Engler, a professor in the Shu Chien-Gene Lay Department of Bioengineering at the UC San Diego Jacobs School of Engineering. “If we can improve diagnostic capabilities with this method, we could better personalize treatment plans based on the tumors that patients have.”
Previous research by Engler’s lab, in collaboration with Anne Wallace, director of the Comprehensive Breast Health Center at Moores Cancer Center at UC San Diego Health, had already established that weakly adherent cancer cells are more likely to migrate and invade other tissues compared to strongly adherent cells. Now with patient tumors, the team has taken this insight a step further, demonstrating that adhesion strength of tumor cells is variable and the next step will be to determine if adhesion can help forecast whether a patient’s cancer is likely to metastasize.

Their latest study examined cell adhesion in an early-stage breast cancer known as ductal carcinoma in situ (DCIS). Often classified as stage zero breast cancer, DCIS can remain harmless, never progressing beyond the milk ducts where it forms. But in some cases, it develops into invasive breast cancer that could be potentially life-threatening. Scientists and doctors have spent years trying to determine which cases require aggressive treatment and which can be left alone, but the answers have remained elusive.
Current clinical decisions often rely on the size and grade of the DCIS lesion, but these factors do not always predict its behavior.
“Having a mechanism to better predict which DCIS is going to behave more aggressively, such as is seen with this adhesion model, could hold great promise to help us more aggressively treat this type of cancer,” Wallace said. “We don’t want to over-treat with aggressive surgery, medicines, and radiation if not necessary, but we need to utilize those when the cancer has higher invasive potential. We want to continue to personalize therapy.”
“Right now, we don’t have a reliable way to identify which DCIS patients are at risk of developing more aggressive breast cancer,” Engler said. “Our device could change that.”
The Microfluidic Device: How It Measures Adhesion
The team’s device, which is roughly the size of an index card, consists of microfluidic chambers coated with adhesive proteins found in breast tissue, such as fibronectin. When tumor cells are placed into the chambers, they adhere to the fibronectin coating. They are then subjected to increasing shear stress as fluid flows through the chambers. By observing where cells detach under specific stress levels, researchers classify them as weakly or strongly adherent.
The team tested the device on samples from 16 patients. These samples consisted of normal breast tissue, DCIS tumors, and aggressive breast cancer tumors obtained from patients with invasive ductal and lobular carcinomas. The experiments revealed that aggressive breast cancer samples contained weakly adherent cells, while normal breast tissue samples contained strongly adherent cells. DCIS samples showed intermediate adhesion levels, but with significant variability among patients.

“What’s interesting is that there is a lot of heterogeneity from patient to patient within a single disease subtype,” said study co-first author Madison Kane, a bioengineering Ph.D. student in Engler’s lab. “Among DCIS patients, for example, we found some with strongly adherent tumor cells and others with weakly adherent cells. We hypothesize that those with weakly adherent cells are at higher risk of developing invasive cancer, and they are likely being underdiagnosed at the beginning of their patient care plan.”
The team plans to track DCIS patients over the next five years to determine whether adhesion strength correlates with metastatic progression. If their hypothesis holds, the device could offer oncologists a powerful new tool to guide treatment strategies, recommending more aggressive interventions for patients whose tumor cells show weak adhesion.
“Our hope is that this device will allow us to prospectively identify those at highest risk, so that we can intervene before metastasis occurs,” Engler said.
This project highlights the importance of interdisciplinary collaboration. Engler’s bioengineering team worked closely with Wallace’s team at Moores Cancer Center, which provided patient samples and support. Funding from the National Institutes of Health (NIH), which includes grants that support shared resources and facilities at Moores Cancer Center, as well as training grants for student researchers working on the project, played a crucial role in the device’s development and the clinical study.
“It’s been a great partnership with Dr. Wallace and Moores Cancer Center,” Engler said. “Their support has been instrumental in advancing investigator-initiated trials like this. We are also extremely grateful for all the different funding mechanisms that support facilities, training, and lab work, which make research like this possible.”
Reference: “Adhesion strength of tumor cells predicts metastatic disease in vivo” by Madison A. Kane, Katherine G. Birmingham, Benjamin Yeoman, Neal Patel, Hayley Sperinde, Thomas G. Molley, Pranjali Beri, Jeremy Tuler, Aditya Kumar, Sarah Klein, Somaye Zare, Anne Wallace, Parag Katira and Adam J. Engler, 5 March 2025, Cell Reports.
DOI: 10.1016/j.celrep.2025.115359
This work was supported by the National Institutes of Health (R01CA280279, R01CA206880 and R21CA217735), the National Science Foundation (CMMI-1763139, CMMI-1763132), Cy pres research awards from the Krueger v. Wyeth settlement fund, and the National Cancer Institute (T32CA009523).

News
Specially engineered antibody delivers RNA therapy to treatment-resistant tumors
Elias Quijano, PhD; Diana Martinez-Saucedo, PhD; Zaira Ianniello, PhD; and Natasha Pinto-Medici, PhD, there are 25 other contributors, most from Yale's Department of Therapeutic Radiology and from the departments of genetics, molecular biophysics and [...]
Vaccinated women face fewer cervical cancer risks
New data from Denmark shows the HPV vaccine’s powerful long-term impact, while also revealing why cervical cancer screening is still essential. A Danish study published in the journal Eurosurveillance reports that women who received the human [...]
3D-printed implant offers a potential new route to repair spinal cord injuries
A research team at RCSI University of Medicine and Health Sciences has developed a 3-D printed implant to deliver electrical stimulation to injured areas of the spinal cord, offering a potential new route to [...]
Nanocrystals Carrying Radioisotopes Offer New Hope for Cancer Treatment
The Science Scientists have developed tiny nanocrystal particles made up of isotopes of the elements lanthanum, vanadium, and oxygen for use in treating cancer. These crystals are smaller than many microbes and can carry isotopes of [...]
New Once-a-Week Shot Promises Life-Changing Relief for Parkinson’s Patients
A once-a-week shot from Australian scientists could spare people with Parkinson’s the grind of taking pills several times a day. The tiny, biodegradable gel sits under the skin and releases steady doses of two [...]
Weekly injectable drug offers hope for Parkinson’s patients
A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, potentially replacing the need for multiple daily tablets. Scientists from the University of South Australia [...]
Most Plastic in the Ocean Is Invisible—And Deadly
Nanoplastics—particles smaller than a human hair—can pass through cell walls and enter the food web. New research suggest 27 million metric tons of nanoplastics are spread across just the top layer of the North [...]
Repurposed drugs could calm the immune system’s response to nanomedicine
An international study led by researchers at the University of Colorado Anschutz Medical Campus has identified a promising strategy to enhance the safety of nanomedicines, advanced therapies often used in cancer and vaccine treatments, [...]
Nano-Enhanced Hydrogel Strategies for Cartilage Repair
A recent article in Engineering describes the development of a protein-based nanocomposite hydrogel designed to deliver two therapeutic agents—dexamethasone (Dex) and kartogenin (KGN)—to support cartilage repair. The hydrogel is engineered to modulate immune responses and promote [...]
New Cancer Drug Blocks Tumors Without Debilitating Side Effects
A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI. A new cancer drug candidate, developed through a collaboration between Lawrence Livermore National Laboratory (LLNL), BridgeBio Oncology [...]
Scientists Are Pretty Close to Replicating the First Thing That Ever Lived
For 400 million years, a leading hypothesis claims, Earth was an “RNA World,” meaning that life must’ve first replicated from RNA before the arrival of proteins and DNA. Unfortunately, scientists have failed to find [...]
Why ‘Peniaphobia’ Is Exploding Among Young People (And Why We Should Be Concerned)
An insidious illness is taking hold among a growing proportion of young people. Little known to the general public, peniaphobia—the fear of becoming poor—is gaining ground among teens and young adults. Discover the causes [...]
Team finds flawed data in recent study relevant to coronavirus antiviral development
The COVID pandemic illustrated how urgently we need antiviral medications capable of treating coronavirus infections. To aid this effort, researchers quickly homed in on part of SARS-CoV-2's molecular structure known as the NiRAN domain—an [...]
Drug-Coated Neural Implants Reduce Immune Rejection
Summary: A new study shows that coating neural prosthetic implants with the anti-inflammatory drug dexamethasone helps reduce the body’s immune response and scar tissue formation. This strategy enhances the long-term performance and stability of electrodes [...]
Scientists discover cancer-fighting bacteria that ‘soak up’ forever chemicals in the body
A family of healthy bacteria may help 'soak up' toxic forever chemicals in the body, warding off their cancerous effects. Forever chemicals, also known as PFAS (per- and polyfluoroalkyl substances), are toxic chemicals that [...]
Johns Hopkins Researchers Uncover a New Way To Kill Cancer Cells
A new study reveals that blocking ribosomal RNA production rewires cancer cell behavior and could help treat genetically unstable tumors. Researchers at the Johns Hopkins Kimmel Cancer Center and the Department of Radiation Oncology and Molecular [...]